[Recent advances in miR-200c and fibrosis in organs]
Abstract:
In the fibrosis and pterygium of lung, liver, kidney, peritoneum or skin, miR-200c was aberrantly expressed. It has been shown that the regulatory effect of miR-200c on fibrosis in organ was involved in TGF-β-mediated epithelial-mesenchymal transition. The abnormal level of miR-200c in serum may be a basis for early diagnosis of lung fibrosis. Furthermore, miRNA mimics, miRNA agomir, and miRNA inhibitor are potential therapeutic tools for fibrosis. In present review, we summarize the recent progress in relevant studies on the expression and regulatory function of miR-200c and focus on its role in diagnosis, treatment, and prognosis of fibrosis in organ.
Insights
MicroRNA-200c (miR-200c) plays a key role in organ fibrosis by regulating epithelial-mesenchymal transition. Its abnormal expression in serum may aid in early lung fibrosis diagnosis and treatment.
Area of Science:
- Molecular Biology
- Cell Biology
- Pathology
Background:
- Fibrosis, a pathological scarring process, affects organs like the lung, liver, kidney, peritoneum, and skin.
- MicroRNA-200c (miR-200c) exhibits aberrant expression in various fibrotic conditions.
- Transforming growth factor-beta (TGF-β)-mediated epithelial-mesenchymal transition (EMT) is a known mechanism in fibrosis.
Purpose of the Study:
- To review the expression and regulatory functions of miR-200c in organ fibrosis.
- To highlight the role of miR-200c in the diagnosis, treatment, and prognosis of fibrotic diseases.
- To discuss the potential of miR-200c-based therapeutics.
Main Methods:
- Literature review of studies on miR-200c and fibrosis.
- Analysis of miR-200c expression patterns in fibrotic tissues and serum.
- Examination of the molecular mechanisms linking miR-200c to TGF-β-mediated EMT.
Main Results:
- miR-200c is aberrantly expressed in lung, liver, kidney, peritoneum, and skin fibrosis.
- miR-200c regulates fibrosis through TGF-β-mediated EMT.
- Abnormal serum miR-200c levels show potential for early lung fibrosis diagnosis.
Conclusions:
- miR-200c is a significant regulator in organ fibrosis.
- miR-200c holds promise as a diagnostic biomarker for lung fibrosis.
- miRNA-based therapeutics, including mimics and inhibitors, represent potential treatment strategies for fibrosis.
